Categories: News

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2022 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 8768458. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

Staff

Recent Posts

Dendi and Molecular Lab Partners Announce Strategic Partnership to Empower Labs Nationwide

OVERLAND PARK, Kan., April 15, 2025 /PRNewswire/ -- Dendi, a leading cloud-native laboratory information system (LIS)…

7 hours ago

Hartford HealthCare Earns Modern Healthcare’s Innovators Award

HARTFORD, Conn., April 15, 2025 /PRNewswire/ -- Hartford HealthCare (HHC) is honored to announce that…

7 hours ago

Intero Biosystems from University of Michigan wins Rice Business Plan Competition

Rice Business presents world's largest and richest student startup competition HOUSTON, April 15, 2025 /PRNewswire/…

7 hours ago

Castlight Health Introduces 24/7 Virtual Urgent Care, Connecting Members to Quality Care in Minutes

High-quality care seamlessly integrates with healthcare benefits navigation app to improve member experience and ensure…

7 hours ago

Compex Legal Services Launches Compex Canvass™ — A New Medical Canvassing Solution for Enhanced Investigative Insight

TORRANCE, Calif., April 15, 2025 /PRNewswire/ -- Compex Legal Services, a leading national provider of medical…

13 hours ago

LifeSciKY inks partnership with Thermo Fisher Scientific as Founding Sponsor

Sponsorship will enhance, strengthen resources for the Northern Kentucky-based life sciences and entrepreneurship lab incubator…

13 hours ago